Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Alessia Deglincerti
Biomarkers will be key to winning the race to a successful AD drug. Even then, drugmakers must build the infrastructure for getting therapy to the right patients at the right time.